Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-dNPM-1-TCR.1 in Relapsed or Refractory AML
2023-505806-41-00Phase 2Authorised
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Dec 2023
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MB-dNPM1-TCR.1 in acute myeloid leukemia (AML), sponsored by Miltenyi Biomedicine GmbH. Planned start Dec 2023; status: authorised.
02
Drugs
MB-dNPM1-TCR.1
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-505806-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505806-41-00.